NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- GLP-1 medications have become one of the most talked about weight loss solutions in recent years, but a growing concern is emerging that people may be losing muscle along with the fat. Now, new clinical research is changing that conversation entirely. Recently, Sarah Kennedy, Founder and CEO of Calocurb, conducted a satellite media tour in partnership with D S Simon Media to share the findings of a landmark new study and introduce a 100% natural GLP-1 activator that supports fat loss while preserving muscle, no prescription required.
As the conversation around GLP-1 medications continues to evolve, important questions are emerging about the long-term consequences of muscle loss and what alternatives exist for those seeking a more natural approach. Here are some of the top questions and expert insights from Sarah Kennedy:
What does the latest clinical research reveal and why is it significant in the current GLP-1 conversation?
Kennedy is enthusiastic about what the new data shows. "We are so excited about this new clinical study," she said. Published in Obesity Pillars, the study was conducted on 150 men and women with a BMI between 25 and 35 over six months.
The findings were striking: participants in the treatment group lost a significant amount of weight, and it was almost entirely fat. "This is where the difference is," Kennedy explained. "With GLP-1 medications, you can lose up to 40% of muscle mass within your weight loss. So the conversation is now changing from looking at the scales to looking at body composition."
Why is muscle loss such an important concern for people using GLP-1 medications and what does new data tell us about preserving it?
For Kennedy, the muscle loss question goes far beyond aesthetics. "Muscle is so important for strength, mobility, and healthy aging," she said. "We know as you get older, you will lose about 3% of your muscle per year. So if you're losing up to 40% of muscle in a short time, it's very hard to regain that." The new clinical data offers an encouraging alternative.
Not only did participants in the Calocurb study preserve their muscle mass, they also lost three and a half times the amount of visceral fat compared to the placebo group. "Visceral fat is that fat that sits around your organs, and it's not great," Kennedy noted. "That's what you don't want."
How does naturally activating the body's own GLP-1 work differently from synthetic GLP-1 injections?
Kennedy explains that the key difference lies in working with the body rather than replacing its natural functions. "A lot of people don't realize that we produce our own appetite-suppressing hormones," she said. "It's really a mechanism in your body to tell you when to stop eating." Calocurb works by super-stimulating the body's own natural satiety hormones including GLP-1, CCK, and PYY, when taken about an hour to an hour and a half before a meal. "What it's doing is making you feel full faster," Kennedy said. "That's why we say we're kind of hacking your hunger with Calocurb."
By contrast, prescription GLP-1 medications use a synthetic hormone that mimics the body's natural GLP-1 but with a modified molecule that extends its duration. "It works with your body," Kennedy said of Calocurb, "rather than replacing what your body already knows how to do."
For people who are looking for a natural alternative or who are coming off GLP-1 medications and want to maintain their results, how does Calocurb work and where can people get it?
Calocurb is well suited for several groups of people, Kennedy explained. "You can use it as an alternative if you can't take the side effects, you can't afford it, or you don't want a prescription drug." For those transitioning off GLP-1 medications, it is particularly valuable. "Whenever you're on a synthetic hormone, you've depressed your own natural hormones," she said. "So you really want to kick start that gut-brain axis because you want to maintain that weight loss which you've worked so hard for."
For more information on the science behind Calocurb and to order, visit calocurb.com and use discount code START for 10% off your first order. Calocurb is also available on Amazon and through healthcare practitioners across the US.
Founder and CEO, Calocurb
Sarah Kennedy is the Founder and CEO of Calocurb, a revolutionary weight management product, commercialized after 15 years and $30 million of New Zealand Government backed science.
Sarah was formerly with Fonterra and held roles as Vice President International Farming based in China, Managing Director of Dairy Nutrition, and Managing Director of RD1-Fonterra’s chain of rural retail stores. Prior to joining Fonterra in 2011 she had more than 20 years’ experience in dietary and animal nutrition, including ten years as Managing Director of Healtheries/Vitaco NZ Ltd.
During her time at Healtheries, she trebled the company revenue and then oversaw the merger of Healtheries and Nutralife to form Vitaco the third largest health and wellbeing company in the Australasian market. She is originally a veterinarian by training and has held a number of other senior executive positions in agribusiness and food industries.
In 2009/2010 Sarah completed a Sloan Fellowship Program in Global Leadership and Innovation at Massachusetts Institute of Technology with 110 other Sloans selected from around the world. Sarah has held a number of board positions with Government, private, philanthropic and listed NZ companies.
Calocurb currently sells in five international markets and continues to grow rapidly through channels and geographies.
About Calocurb® and Amarasate®
Amarasate® is a natural extract from a specific New Zealand bitter hop and is the active ingredient in Calocurb®, which has been demonstrated in 3 previous, published, human clinical trials to activate endogenous GLP-1, CCK and PYY release and reduce appetite by 30%, cravings by 40%, and caloric intake by an average of 18% in one hour. Calocurb is a non-prescription capsule taken on an empty stomach twice a day. The capsule releases in the small intestine and super-stimulates the body’s own GLP-1, CCK and PYY when Amarasate® interacts with bitter taste receptors, or TAS2Rs, in the small intestine. This activates satiety hormones that send a signal to the appetite center in the brain communicating its feeling fuller before eating which results in behavioral change. All three hormones support satiety, while CCK promotes fat oxidation and PYY supports muscle preservation. Together, this triple hormone activation improves body composition through weight loss, fat loss, and muscle preservation. Calocurb, at $89.99 for a month’s supply, is an affordable solution for those wanting a proven, natural solution to weight health, and for those coming off GLP-1 injectables to maintain weight lost. Calocurb is used extensively in the US by both practitioners and consumers.
About D S Simon Media:
The firm is well known as a leader in the satellite media tour industry and produces tours from its studio and multiple control rooms at its New York headquarters. Clients include top brands in healthcare, technology, travel, financial services, consumer goods, entertainment, retail and non-profits. Established in 1986 the firm has won more than 100 industry awards.
About YourUpdateTV: YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of Calocurb®.
Media Contact
Michael O’Donnell
D S Simon Media
212-736-2727
modonnell@dssimon.com
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/313cd24c-a935-4ccd-aaac-84804f3e30d4
